Provectus CEO converts $25K note into preferred

PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings.

Rhea-AI Filing Summary

PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings. On the transactions date, an 8% unsecured convertible promissory note converted into 9,436 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 94,360 additional common shares. After these derivative exercises and conversions, Pershing directly owns 2,857,285 shares of common stock. These were conversions of existing securities, not open-market purchases or sales.

Insider Trade Summary

9,436 shares exercised/converted

Exercise 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note	0	$0.00	$0.00
Exercise	Series D-1 Convertible Preferred Stock	9,436	$0.00	$0.00

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 contracts (Direct); Series D-1 Convertible Preferred Stock — 2,857,285 contracts (Direct)

Footnotes (4)

1. F1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
2. F2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
3. F3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
4. F4. On June 05, 2026, the 2025 Note was converted into 9,436 shares of Series D-1 Preferred Stock.

Key Figures

Common shares acquired: 94,360 shares Preferred shares issued: 9,436 shares Note conversion price: $2.862 per preferred share +3 more

6 metrics

Common shares acquired 94,360 shares Common stock received from converting Series D-1 Preferred on transaction date

Preferred shares issued 9,436 shares Series D-1 Convertible Preferred Stock from 8% note conversion

Note conversion price $2.862 per preferred share Conversion of 8% unsecured convertible promissory note into Series D-1 Preferred

Post-transaction common holdings 2,857,285 shares Common stock directly owned after derivative exercises and conversions

Preferred-to-common ratio 10 common per 1 preferred Conversion ratio for Series D-1 Convertible Preferred Stock into common stock

Automatic conversion date December 31, 2028 Automatic conversion of Series D-1 Preferred into common if not earlier converted

Key Terms

Series D-1 Convertible Preferred Stock, 8% unsecured convertible promissory note, Certificate of Designation, 2025 Financing

4 terms

Series D-1 Convertible Preferred Stock financial

"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"

8% unsecured convertible promissory note financial

"The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note"

Certificate of Designation regulatory

"in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

2025 Financing financial

"The 2025 Note was issued pursuant to the Issuer's 2025 Financing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PVCT CEO Edward Pershing report in this Form 4 filing?

Edward Pershing reported exercising convertible securities to acquire more PROVECTUS BIOPHARMACEUTICALS (PVCT) common stock. An 8% unsecured convertible note converted into Series D-1 preferred shares, which then converted into 94,360 common shares, increasing his direct ownership.

How many PVCT common shares did Edward Pershing acquire through these conversions?

Edward Pershing acquired 94,360 shares of PROVECTUS BIOPHARMACEUTICALS (PVCT) common stock. These shares resulted from converting 9,436 Series D-1 Convertible Preferred Stock shares, which themselves came from converting an 8% unsecured convertible promissory note.

What is the conversion ratio of PVCT Series D-1 Convertible Preferred Stock?

Each share of PROVECTUS BIOPHARMACEUTICALS (PVCT) Series D-1 Convertible Preferred Stock is convertible into 10 common shares. In this filing, 9,436 preferred shares were effectively converted, producing 94,360 additional shares of common stock for the reporting person.

What was the conversion price for the PVCT 8% unsecured convertible promissory note?

The 8% unsecured convertible promissory note of PROVECTUS BIOPHARMACEUTICALS (PVCT) converted into Series D-1 preferred stock at $2.862 per preferred share. This automatic conversion created 9,436 preferred shares, which are themselves convertible into common stock at a fixed 10-to-1 ratio.

How many PVCT common shares does Edward Pershing own after these transactions?

Following the reported derivative exercises and conversions, Edward Pershing directly owns 2,857,285 shares of PROVECTUS BIOPHARMACEUTICALS (PVCT) common stock. This total reflects the addition of 94,360 new common shares obtained from converting previously held convertible securities.

Was this PVCT insider transaction an open-market buy or sell of shares?

The PROVECTUS BIOPHARMACEUTICALS (PVCT) transactions were derivative exercises and conversions, not open-market buys or sells. An 8% unsecured convertible note converted into Series D-1 preferred shares, which then converted into additional common stock held directly by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 02:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	06/05/2026		M			$25,000	06/05/2025	06/05/2026	Series D-1 Convertible Preferred Stock(3)(4)	9,436	$0	$860,000	D
Series D-1 Convertible Preferred Stock	(1)	06/05/2026		M		9,436		06/05/2026	(2)	Common Stock	94,360	$0	2,857,285	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On June 05, 2026, the 2025 Note was converted into 9,436 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)